0001144204-17-051541.txt : 20171005 0001144204-17-051541.hdr.sgml : 20171005 20171005172635 ACCESSION NUMBER: 0001144204-17-051541 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170901 FILED AS OF DATE: 20171005 DATE AS OF CHANGE: 20171005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dusseux Eric Michel CENTRAL INDEX KEY: 0001713593 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-54717 FILM NUMBER: 171125329 MAIL ADDRESS: STREET 1: 1 RUE DU CAPOT CITY: CALUIRE-ET-CUIRE STATE: I0 ZIP: 69300 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bionik Laboratories Corp. CENTRAL INDEX KEY: 0001508381 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 271340346 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 483 BAY STREET STREET 2: N105 CITY: TORONTO STATE: A6 ZIP: M5G2C9 BUSINESS PHONE: 1.416.640.7887 MAIL ADDRESS: STREET 1: 483 BAY STREET STREET 2: N105 CITY: TORONTO STATE: A6 ZIP: M5G2C9 FORMER COMPANY: FORMER CONFORMED NAME: Drywave Technologies, Inc. DATE OF NAME CHANGE: 20130814 FORMER COMPANY: FORMER CONFORMED NAME: Strategic Dental Management Corp. DATE OF NAME CHANGE: 20101220 4/A 1 v476557_4a.xml OWNERSHIP DOCUMENT X0306 4/A 2017-09-01 2017-09-15 0 0001508381 Bionik Laboratories Corp. BNKL 0001713593 Dusseux Eric Michel C/O BIONIK LABORATORIES CORP. 483 BAY STREET, N105 TORONTO A6 M5G2C9 ONTARIO, CANADA 1 1 0 0 Chief Executive Officer Employee Stock Option (Right to Buy) 0.161 2017-09-01 4 A 0 6122677 0 A 2027-09-01 Common Stock, par value $0.001 6122677 6122677 D This amendment to the Statement of Change in Beneficial Ownership on Form 4, originally filed with the Securities and Exchange Commission on September 15, 2017, is being filed to correct an administrative error concerning the number of shares of stock options granted to the reporting person. One-sixth of the option will be vested and exercisable as of the September 1, 2017 date of grant, and the unvested portion of the option will become vested and exercisable as follows: (a) 50% in 5 equal annual installments on each of the five anniversaries of the date of the issuance of the option; and (b) 50% in 5 equal separate tranches annually based on Dr. Dusseux's achievement of annual performance goals to be established by the Board in consultation with Dr. Dusseux. The extent to which each separate tranche becomes vested shall be determined by reference to Dr. Dusseux's annual performance as measured by reference to the performance targets set for that performance period. In the event a specific tranche is not fully vested, that tranche shall not be forfeited, but shall remain outstanding, and may become vested as a result of Dr. Dusseux's future performance at an above target level or as a result of accelerated vesting on the occurrence of any other event that triggers accelerated vesting. /s/ Eric Michel Dusseux 2017-10-05